Quarterly report pursuant to Section 13 or 15(d)

RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

v3.8.0.1
RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE
3 Months Ended
Mar. 31, 2018
Research And Development Tax Rebate Receivable  
RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

 

On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the three months ended March 31, 2018, the Company incurred qualified R&D expenses of approximately $86,000 resulting in an increase to the R&D rebate receivable of approximately $38,000 from the December 31, 2017 balance, and a corresponding offset to R&D expenses in the same amount. At March 31, 2018, we had a total R&D rebate receivable of approximately $396,000.